Switch to:
Also traded in: Denmark, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GNMSF's Cash to Debt is ranked higher than
88% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. GNMSF: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GNMSF' s Cash to Debt Range Over the Past 10 Years
Min: 10.54  Med: 2677.54 Max: 59161.39
Current: No Debt
10.54
59161.39
Equity to Asset 0.91
GNMSF's Equity to Asset is ranked higher than
86% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GNMSF: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
GNMSF' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.47 Max: 0.91
Current: 0.91
0.21
0.91
Interest Coverage 10.54
GNMSF's Interest Coverage is ranked lower than
86% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNMSF: 10.54 )
Ranked among companies with meaningful Interest Coverage only.
GNMSF' s Interest Coverage Range Over the Past 10 Years
Min: 10.68  Med: 6189.65 Max: No Debt
Current: 10.54
F-Score: 6
Z-Score: 104.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 49.12
GNMSF's Operating margin (%) is ranked higher than
97% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. GNMSF: 49.12 )
Ranked among companies with meaningful Operating margin (%) only.
GNMSF' s Operating margin (%) Range Over the Past 10 Years
Min: -348.38  Med: -49.34 Max: 64.46
Current: 49.12
-348.38
64.46
Net-margin (%) 49.87
GNMSF's Net-margin (%) is ranked higher than
97% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. GNMSF: 49.87 )
Ranked among companies with meaningful Net-margin (%) only.
GNMSF' s Net-margin (%) Range Over the Past 10 Years
Min: -323.31  Med: -86.46 Max: 67.39
Current: 49.87
-323.31
67.39
ROE (%) 20.72
GNMSF's ROE (%) is ranked higher than
93% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. GNMSF: 20.72 )
Ranked among companies with meaningful ROE (%) only.
GNMSF' s ROE (%) Range Over the Past 10 Years
Min: -112.03  Med: -29.6 Max: 27.67
Current: 20.72
-112.03
27.67
ROA (%) 18.33
GNMSF's ROA (%) is ranked higher than
96% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. GNMSF: 18.33 )
Ranked among companies with meaningful ROA (%) only.
GNMSF' s ROA (%) Range Over the Past 10 Years
Min: -36.89  Med: -20.21 Max: 22.56
Current: 18.33
-36.89
22.56
ROC (Joel Greenblatt) (%) 2417.90
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. GNMSF: 2417.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNMSF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -675.71  Med: -31.43 Max: 2780.55
Current: 2417.9
-675.71
2780.55
Revenue Growth (3Y)(%) 21.00
GNMSF's Revenue Growth (3Y)(%) is ranked higher than
75% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. GNMSF: 21.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNMSF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.2 Max: 326.8
Current: 21
0
326.8
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:GRFS, NAS:MDVN, NAS:JAZZ, NAS:ALKS, NAS:INCY, NAS:SGEN, OTCPK:UCBJF, NAS:ALNY, NAS:BMRN, NAS:UTHR, NAS:ANAC, NAS:TSRO, OTCPK:ALIOY, NAS:TECH, NAS:ICPT, NAS:ACAD, NAS:IONS, NAS:JUNO, NYSE:XON, NAS:CBPO » details
Traded in other countries:GEN.Denmark, 0MGB.UK,
Genmab A/S is an antibody company focused on cancer. Its first marketed product is Arzerra (ofatumumab); development pipeline incl. daratumumab and two proprietary technology platforms; DuoBody (bispecifics) & HexaBody (effector function enhancement).

Genmab A/S is a biotechnology company that utilizes antibody products. The Company's treatments focus on cancer and other serious illnesses. The Company has a pipeline of drugs in various stages of development and approval. The Company has licensed rights to HuMAb-Mouse, a transgenic mouse technology designed by Medarex. The platform produces high affinity human antibodies. Using the technology also circumvents the need for humanization or genetic engineering which can often drag out drug development. The Company also uses its proprietary UniBody platform. UniBody also binds to one site and produces no immune response. HuMax-CD38 is a drug in development for the treatment of multiple myeloma. The Company also has treatments for asthma (R1671 and R4930), peripheral vascular disease (R1512), hepatitis C (HuMax-HepC), organ transplant rejection (HuMax-TAC), cancer (HuMax-CD32b), and oncology (HuMax-TF). The Company has a myriad of other products in development, pending completion and approval. The Company owns its own manufacturing facilities. Within the facilities, it has the capabilities of producing multiple antibody products simultaneously.

Ratios

vs
industry
vs
history
P/E(ttm) 96.99
GNMSF's P/E(ttm) is ranked lower than
82% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.85 vs. GNMSF: 96.99 )
Ranked among companies with meaningful P/E(ttm) only.
GNMSF' s P/E(ttm) Range Over the Past 10 Years
Min: 42.72  Med: 85.6 Max: 133.3
Current: 96.99
42.72
133.3
PE(NRI) 96.99
GNMSF's PE(NRI) is ranked lower than
82% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 96.99 )
Ranked among companies with meaningful PE(NRI) only.
GNMSF' s PE(NRI) Range Over the Past 10 Years
Min: 42.64  Med: 85.34 Max: 181.04
Current: 96.99
42.64
181.04
Price/Owner Earnings (ttm) 152.22
GNMSF's Price/Owner Earnings (ttm) is ranked lower than
82% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 30.57 vs. GNMSF: 152.22 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GNMSF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 152.22  Med: 322.57 Max: 679.38
Current: 152.22
152.22
679.38
P/B 17.46
GNMSF's P/B is ranked lower than
90% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. GNMSF: 17.46 )
Ranked among companies with meaningful P/B only.
GNMSF' s P/B Range Over the Past 10 Years
Min: 1.63  Med: 7.65 Max: 25.04
Current: 17.46
1.63
25.04
P/S 47.62
GNMSF's P/S is ranked lower than
77% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. GNMSF: 47.62 )
Ranked among companies with meaningful P/S only.
GNMSF' s P/S Range Over the Past 10 Years
Min: 3.08  Med: 14.29 Max: 66.78
Current: 47.62
3.08
66.78
PFCF 115.75
GNMSF's PFCF is ranked lower than
86% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 26.42 vs. GNMSF: 115.75 )
Ranked among companies with meaningful PFCF only.
GNMSF' s PFCF Range Over the Past 10 Years
Min: 3.76  Med: 73.1 Max: 7364.2
Current: 115.75
3.76
7364.2
POCF 110.86
GNMSF's POCF is ranked lower than
91% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. GNMSF: 110.86 )
Ranked among companies with meaningful POCF only.
GNMSF' s POCF Range Over the Past 10 Years
Min: 3.66  Med: 116.34 Max: 1654.96
Current: 110.86
3.66
1654.96
EV-to-EBIT 90.94
GNMSF's EV-to-EBIT is ranked lower than
87% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 23.94 vs. GNMSF: 90.94 )
Ranked among companies with meaningful EV-to-EBIT only.
GNMSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -390.6  Med: 0.6 Max: 1407.7
Current: 90.94
-390.6
1407.7
EV-to-EBITDA 90.94
GNMSF's EV-to-EBITDA is ranked lower than
88% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 19.79 vs. GNMSF: 90.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNMSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1007.1  Med: 0.7 Max: 1407.7
Current: 90.94
-1007.1
1407.7
Current Ratio 10.33
GNMSF's Current Ratio is ranked higher than
78% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. GNMSF: 10.33 )
Ranked among companies with meaningful Current Ratio only.
GNMSF' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 1.88 Max: 10.33
Current: 10.33
1.3
10.33
Quick Ratio 10.33
GNMSF's Quick Ratio is ranked higher than
78% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. GNMSF: 10.33 )
Ranked among companies with meaningful Quick Ratio only.
GNMSF' s Quick Ratio Range Over the Past 10 Years
Min: 1.3  Med: 1.88 Max: 10.33
Current: 10.33
1.3
10.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.80
GNMSF's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. GNMSF: -5.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNMSF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.9  Med: -5.8 Max: -0.2
Current: -5.8
-19.9
-0.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.35
GNMSF's Price/Net Cash is ranked lower than
80% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. GNMSF: 19.35 )
Ranked among companies with meaningful Price/Net Cash only.
GNMSF' s Price/Net Cash Range Over the Past 10 Years
Min: 7.38  Med: 13.99 Max: 75.2
Current: 19.35
7.38
75.2
Price/Net Current Asset Value 18.55
GNMSF's Price/Net Current Asset Value is ranked lower than
84% of the 618 Companies
in the Global Biotechnology industry.

( Industry Median: 5.45 vs. GNMSF: 18.55 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNMSF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.72  Med: 7.76 Max: 24.04
Current: 18.55
1.72
24.04
Price/Tangible Book 18.33
GNMSF's Price/Tangible Book is ranked lower than
87% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. GNMSF: 18.33 )
Ranked among companies with meaningful Price/Tangible Book only.
GNMSF' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 7.6 Max: 22.66
Current: 18.33
1.62
22.66
Price/Projected FCF 15.71
GNMSF's Price/Projected FCF is ranked lower than
82% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. GNMSF: 15.71 )
Ranked among companies with meaningful Price/Projected FCF only.
GNMSF' s Price/Projected FCF Range Over the Past 10 Years
Min: 15.71  Med: 31.29 Max: 407.96
Current: 15.71
15.71
407.96
Price/Median PS Value 3.34
GNMSF's Price/Median PS Value is ranked lower than
91% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. GNMSF: 3.34 )
Ranked among companies with meaningful Price/Median PS Value only.
GNMSF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 1.05 Max: 3.69
Current: 3.34
0.25
3.69
Price/Graham Number 8.89
GNMSF's Price/Graham Number is ranked lower than
89% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.78 vs. GNMSF: 8.89 )
Ranked among companies with meaningful Price/Graham Number only.
GNMSF' s Price/Graham Number Range Over the Past 10 Years
Min: 4.02  Med: 6.6 Max: 10.79
Current: 8.89
4.02
10.79
Earnings Yield (Greenblatt) (%) 1.10
GNMSF's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. GNMSF: 1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNMSF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.2 Max: 371.6
Current: 1.1
0.1
371.6

More Statistics

Revenue (TTM) (Mil) $204.5
EPS (TTM) $ 1.67
Beta0.52
Short Percentage of Float0.00%
52-Week Range $84.70 - 183.00
Shares Outstanding (Mil)59.83
» More Articles for GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma Aug 23 2016
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in... Aug 17 2016
Genmab Enters Commercial License Agreement with Gilead for DuoBody(R) Technology Aug 10 2016
Genmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance Aug 09 2016
Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More Aug 08 2016
Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in... Jul 25 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : July 25, 2016 Jul 25 2016
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion Jun 24 2016
Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as... Jun 23 2016
Market Rout Hits Genmab While Buy Ratings Signal 20% Rebound Jun 13 2016
Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis Jun 02 2016
Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen May 30 2016
Genmab A/S :GNMSF-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
Genmab A/S: Leads amongst peers with strong fundamentals Apr 08 2016
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : March 1, 2016 Mar 01 2016
Genmab A/S Earnings Analysis: 2015 By the Numbers Feb 24 2016
Genmab A/S : Undervalued relative to peers, but don’t ignore the other factors Feb 10 2016
Genmab A/S – Value Analysis (US OTC:GNMSF) : January 29, 2016 Jan 29 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : January 29, 2016 Jan 29 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : October 16, 2015 Oct 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)